Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage

• Status: Recruiting
• Trial end date: 2025-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

To determine the effectiveness of using two medications simultaneously versus one medication, as is standard of care, in preventing early postpartum hemorrhage.

There have been studies that looked at giving two medications and that there were reduced odds of postpartum hemorrhage.

Specific Aim 1: Determine if double simultaneous uterotonic agent regimen (misoprostol and oxytocin) is superior to single agent (oxytocin only) in reducing postpartum hemorrhage.

Specific Aim 2: Determine any potential side effects of a double simultaneous uterotonic agentregimen (misoprostol and oxytocin) versus a single agent (oxytocin only).

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Stony Brook University
• Treatments: Misoprostol; Oxytocin

Criteria

Inclusion Criteria:

• All women 18 years and older admitted to delivery at Stony Brook University hospital who agree to participate in the study

Exclusion Criteria:

• Women under 18 years old

• Women with known coagulation disorders

• Women with planned cesarean hysterectomy

• Women with known placental accreta spectrum disorders

• Women with known allergy to prostaglandins